Steroid drug addition to MS treatment effective for reducing disease activityThe use of a steroid drug, methylprednisolone, in addition to a multiple sclerosis (MS) drug can prove to be a more effective combination for reducing the volume of disease activity than the use of MS drug alone.

This finding was presented as part of the Late-breaking Science Program at the American Academy of Neurology’s 61st Annual Meeting in Seattle, April 25 – May 2, 2009.

From Sciencedaily.com:

The study involved 341 people with relapsing-remitting MS. Half of the participants received both drugs; half received only the interferon drug plus a placebo. The participants were seen every three months during the three-year study for evaluation.

The participants had the disease for an average of three years and had not yet received a disease-modifying drug such as interferon.

Those who received both drugs had 38 percent fewer relapses, or times when the disease is active, than those receiving only the interferon drug. They also improved slightly on a test of MS disability, while the scores for the placebo group decreased slightly.

At the beginning of the study and again after three years, the researchers measured the size of lesions in the brain that are a sign of disease activity. For those receiving both drugs, the lesions stayed the same size or shrunk, while the size of the lesions grew for those taking only interferon.

Study author Mads Ravnborg, MD, of the Danish Multiple Sclerosis Research Center at Copenhagen University Hospital in Denmark, remarked that the results suggest that both drugs seem to have a synergy when taken as a combination and offer a more beneficial effect on the disease activity.